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Background
CAPS encompasses a spectrum of three phenotypes:
familial cold auto-inflammatory syndrome (FCAS),
Muckle-Wells syndrome (MWS), and chronic infantile
neurologic cutaneous and articular syndrome/neonatal
onset multisystem inflammatory disease (CINCA/
NOMID)[1]. The b-Confident Registry, the largest
CAPS cohort documented in a registry, enrolled the last
patient in December 2014. Here, we report interim data
for the complete cohort of enrolled patients.
Objectives
To monitor the overall safety of canakinumab (CAN)
focusing on SAEs including serious infections, vertigo,
malignancies, and hypersensitivity reactions.
Patients and methods
The registry protocol does not mandate any visits or pro-
cedures, but records all observed and reported AEs and
SAEs or AEs potentially CAN-related. Cumulative safety
data are reported as incidence rate per 100 patient-years
(IR/100 pyr). Data is partial for 11 patients due to the
cut-off date for the analysis and will be updated at a later
date. Efficacy was measured using physician global
assessments (PGA).
Results
288 patients were enrolled with a mean±SD duration of
193±72 weeks. Of these, 21 (7.3%) patients discontinued
CAN: 5 each due to AE, poor efficacy and patient prefer-
ence; and 6 due to unknown reasons. The IR/100 pyr for
overall AEs was 100.0. FCAS patients had the lowest AE
IR/100 pyr (60.9) compared with MWS (IR/100 pyr 107.2)
and NOMID (IR/100 pyr 120.3) patients. The most com-
mon types of AEs were infections and infestations (IR/100
pyr 36.7). Vertigo was reported by 19 patients (IR/100 pyr
3.7). 117 SAEs were reported by 62 patients (IR/100 pyr
15.0), with infection being the most common (IR/100 pyr
4.1). One death (metastatic rectal adenocarcinoma in 76 yr
old MWS patient) was reported. Of 18 patients receiving
pneumococcal vaccinations (PPV), 13 (72%) reported a
local post-PPV injection site reaction, of which 5 were
considered as serious. Based on PGA, nearly half the
patients had no disease activity while most others had
mild/moderate disease activity. Similarly, disease activity
was mostly absent in NLRP3 mutation negative CAPS
patients (n=14) treated with CAN. There was no evidence
of loss of effect with time. Further analyses of this cohort
are ongoing.
Conclusions
Canakinumab demonstrated a safety profile consistent
with that observed in the clinical trial program and
provided continued effectiveness in CAPS patients for up
to 5 years. Canakinumab therapy was also effective in
NLRP3 mutation negative CAPS patients.
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